Plain-English translation of NCT05564377 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
ComboMATCH is a large research study that matches patients with advanced cancers to specific two-drug combinations based on genetic changes found in their tumors. The study uses and as examples of these targeted medications—drugs designed to work against specific genetic mutations. By tailoring treatment to your cancer's unique genetic profile, researchers hope to find combinations that work better than standard one-drug treatments.
Many patients with advanced cancers stop responding to standard treatments, and doctors don't have clear guidance on what to try next. This trial exists to test whether combining two targeted medications chosen specifically for each person's tumor genetics can be more effective than treating everyone with the same approach.
You likely qualify if…
You likely don't qualify if…
First, your tumor will be tested for specific genetic mutations to see if you match one of the study's treatment groups. If you do, you'll take two oral medications daily in 28-day cycles for up to 5 years, with regular scans and blood tests to check how well the treatment is working. You may also be asked to have a new biopsy before treatment starts and possibly another one if your cancer progresses, and you can choose to provide blood samples for research throughout the trial.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
United States